Twice-Yearly Alzheimer’s Injection: Promising Signal, Long Odds
A twice-yearly tau-lowering injection reported a 54% slowing of cognitive decline. The signal justifies Phase 3, but the trial missed its primary endpoint, the best dose was the smallest, and Alzheimer’s drugs rarely survive Phase 3. Here is the evidence, the odds, and the earliest realistic release.


